The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries

PLoS Neglected Tropical Diseases

Volumn 10, Issue 12, 2016, Pages

  Aguiar, Maíra ^a   Stollenwerk, Nico ^a   Halstead, Scott B ^b  

^a UNIVERSITY OF LISBON   (Portugal)

^b Uniformed Services University of the Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

AGE; ARTICLE; BAYES THEOREM; CLINICAL TRIAL (TOPIC); CROSS PROTECTION; DENGUE; DRUG EFFICACY; ENDEMIC DISEASE; HEALTH IMPACT ASSESSMENT; HOSPITAL PATIENT; HUMAN; LICENCE; MASS SCREENING; MATHEMATICAL MODEL; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); SEROPREVALENCE; SOUTH AND CENTRAL AMERICA; ADOLESCENT; ADULT; CHILD; DENGUE VIRUS; ENDEMIC DISEASES; FEMALE; HOSPITALIZATION; IMMUNOLOGY; LEGISLATION AND JURISPRUDENCE; MALE; MIDDLE AGED; SEVERE DENGUE; STANDARDS; STATISTICS AND NUMERICAL DATA; VACCINATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CLINICAL TRIALS, PHASE III AS TOPIC; DENGUE; DENGUE VACCINES; DENGUE VIRUS; ENDEMIC DISEASES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; SEVERE DENGUE; VACCINATION; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 85009106607     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0005179     Document Type: Article

References (50)

1. Halstead S. B., (1994). Antibody-dependent Enhancement of Infection: A Mechanism for Indirect Virus Entry into Cells. Cellular Receptors for Animal Viruses, 28, Chapter 25, 493–516, ISBN 0-87969-429-7. (Cold Spring Harbor Laboratory Press).
2. Halstead S.B., (1982). Immune enhancement of viral infection. Progress in Allergy, 31, 301–364, ISSN 0079-6034. 6292921
3. Halstead S.B., (2003). Neutralization and antibody-dependent enhancement of dengue viruses. Advances in Virus Research, 60, 421–467. doi: 10.1016/S0065-3527(03)60011-414689700
4. Mackenzie J. S., Gubler D. J., Petersen L. R., (2004). Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nature Medicine Review, 12, S98–S109. doi: 10.1038/nm114415577938
5. Dejnirattisai W., et al. (2010). Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans. Science, 328, 745–748. doi: 10.1126/science.118518120448183
6. Guzmán M.G., et al. (2010). Dengue: a continuing global threat. Nature Reviews Microbiology, 8, S7–S16, ISSN: 1740-1526. doi: 10.1038/nrmicro246021079655
7. Ferguson N., Anderson R., Gupta S., (1999). The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens. Proc. Natl. Acad. Sci. USA, 96, 790–94. doi: 10.1073/pnas.96.2.7909892712
8. Schwartz I. B., et al. (2005). Chaotic desynchronization of multi-strain diseases. Physical Review, E72, 066201–6.
9. Billings L., et al. (2007). Instabilities in multiserotype disease models with antibody-dependent enhancement. Journal of Theoretical Biology, 246, 18–27. doi: 10.1016/j.jtbi.2006.12.02317270219
10. Wearing H.J., Rohani P., (2006). Ecological and immunological determinants of dengue epidemicsProc. Natl. Acad. Sci. USA, 103, 11802–11807. doi: 10.1073/pnas.060296010316868086
11. Nagao Y., Koelle K., (2008). Decreases in dengue transmission may act to increase the incidence of dengue hemorrhagic fever. Proc. Natl. Acad. Sci. USA, 105, 2238–2243. doi: 10.1073/pnas.070902910518250338
12. Recker M., et al. (2009). Immunological serotype interactions and their effect on the epidemiological pattern of dengue. Proc. R. Soc. B., 276, 2541–2548. doi: 10.1098/rspb.2009.033119369266
13. Aguiar M., Kooi B., Stollenwerk N., (2008). Epidemiology of dengue fever: A model with temporary cross-immunity and possible secondary infection shows bifurcations and chaotic behaviour in wide parameter regions, Math. Model. Nat. Phenom. 3, 48–70. doi: 10.1051/mmnp:2008070
14. Aguiar M., Ballesteros S., Kooi B.W., Stollenwerk N., (2011) The role of seasonality and import in a minimalistic multi-strain dengue model capturing differences between primary and secondary infections: complex dynamics and its implications for data analysis, Jounal of Theoretical Biology, 289, 181–196. doi: 10.1016/j.jtbi.2011.08.04321907213
15. Aguiar M., Stollenwerk N., Kooi W. B., (2012). Scaling of stochasticity in dengue hemorrhagic fever epidemics. Math. Model. Nat. Phenom., 7, 1–11. doi: 10.1051/mmnp/20127301
16. Aguiar M., Paul R., Sakuntabhai A., Stollenwerk N., (2014). Are we modeling the correct data set? Minimizing false predictions for dengue fever in Thailand. Epidemiology and Infection, 142, 2447–59. doi: 10.1017/S095026881300334825267408
17. Duong V., et al. (2015). Asymptomatic humans transmit dengue virus to mosquitoes. Proc. Natl. Acad. Sci. USA, 112, 14688–93. doi: 10.1073/pnas.150811411226553981
18. Aguiar M., Kooi W. B., Rocha F., Ghaffari P., Stollenwerk N., (2013). How much complexity is needed to describe the fluctuations observed in dengue hemorrhagic fever incidence data?Ecological Complexity, 16, 31–40. doi: 10.1016/j.ecocom.2012.09.001
19. Flipse J., Smit J.M., (2015). The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response. PLoS Negl. Trop. Dis., 9(6): e0003749. doi: 10.1371/journal.pntd.000374926065421
20. Capeding M.R., et al. (2014). Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia:a phase 3, randomised, observer-masked, placebo-controlled trial. The Lancet, 384, 1358–65. doi: 10.1016/S0140-6736(14)61060-625018116
21. Villar L., et al. (2015). Efficacy of a tetravalent dengue vaccine in children in Latin America. New Engl. J. Med., 372, 113–123. doi: 10.1056/NEJMoa141103725365753
22. Sanofi Pasteur Press Release. July 27, 2016. Retrieved from http://www.sanofipasteur.com/en/articles/New-England-Journal-of-Medicine-Publishes-New-Analyses-Confirming-that-Sanofi-Pasteur-s-Vaccine-Candidate-Safely-Protects-Pre-Adolescents-to-Adults-Against-Dengue.aspx Last access on August 15 2016.
23. Coudeville L., Baurin N., Vergu E., (2015). Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies. Vaccine. In Press.
24. Coudeville L., Baurin N., L’Azou M., Guy B., (2016). Potential Impact of Dengue Vaccination: Insights From Two Large-Scale Phase III Trials With a Tetravalent Dengue VaccineVaccine. In Press. doi: 10.1016/j.vaccine.2016.08.05027601343
25. Hadinegoro S.R., Arredondo-Garcia J.L., Capeding M.R., Deseda C., Chotpitayasunondh T., Dietze R., et al. (2015). Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N. Engl. J. Med., 373, 1195–206. doi: 10.1056/NEJMoa150622326214039
26. Halstead Scott B.,. (2016). Protective and Immunological Behavior of Yellow Fever Dengue Chimeric Vaccine. Vaccine, 34(14), 1643–1647. doi: 10.1016/j.vaccine.2016.02.00426873054
27. World Health Organization Strategic Advisory Group of Experts (SAGE) on Immunization. Background paper on Dengue Vaccines prepared by the SAGE working group on dengue vaccines and the WHO secretariat Retrieved from http://www.who.int/immunization/sage/meetings/2016/april/presentations_background_docs/en/ Last access on August 12 2016.
28. World Health Organization Strategic Advisory Group of Experts (SAGE) on Immunization. Comparative modelling of dengue vaccine public health impact (CMDVI) Flasche S. et al. Retrieved from http://www.who.int/immunization/sage/meetings/2016/april/presentations_background_docs/en/ Last access on August 7 2016.
29. Pang Tikki,. (2016). SAGE committee advice on dengue vaccine, The Lancet Infectious Diseases, 16, 880–882. doi: 10.1016/S1473-3099(16)30167-027477966
30. Fierce Vaccines Press Release. 17th February 2016. Retrieved from http://www.fiercevaccines.com/story/sanofi-ships-1m-dengvaxia-doses-philippines-talks-3m-more-20-dose/2016-02-17
31. Sanofi Pasteur Press Release. October 4th, 2016. Retrieved from http://www.sanofipasteur.com/en/articles/first_dengue_vaccine_approved_in_more_than_10_countries.aspx
32. Sanofi Pasteur Press Release. April 4th, 2016. Retrieved from Retrieved from http://www.sanofipasteur.com/en/articles/World-s-First-Public-Dengue-Immunization-Program-Starts-in-the-Philippines.aspx
33. Sanofi Pasteur Press Release. August 13th, 2016. Retrieved from Retrieved from http://www.sanofipasteur.com/en/articles/Dengue-Immunization-Public-Program-in-Parana-State-of-Brazil.aspx
34. Luis Mateus, Maira Aguiar and Nico Stollenwerk. (2015). Bayesian estimation of vaccine efficacy. (2015). Proceedings of the 15th International Conference on Mathematical Methods in Science and Engineering, CMMSE, pp 794-802, ISBN 978-84-617-2230-3 edited by Jesus Vigo Aguiar et al., Almería, Spain.
35. Stollenwerk N., Jansen V.A.A., (2011). Population Biology and Criticality: From critical birth-death processes to self-organized criticality in mutation pathogen systems (Imperial College Press, World Scientific, London, ISBN–13 978–184816–401–7).
36. Mateus L., Stollenwerk N., Zambrini J.C., (2013). Stochastic Models in Population Biology: From Dynamic Noise to Bayesian Description and Model Comparison for Given Data Sets, Int. Journal. Computer Math.90, 2161–2173. doi: 10.1080/00207160.2013.792924
37. Stollenwerk N., Aguiar M., Ballesteros S., Boto J., Kooi W. B., Mateus L., (2012). Dynamic noise, chaos and parameter estimation in population biology, J. Royal Soc. Interface Focus2, 156–169doi: 10.1098/rsfs.2011.010323565331
38. Maíra Aguiar, Luis Mateus and Nico Stollenwerk. (2015). The currently best estimate for worldwide dengue vaccine efficacy. AIP Conference Proceedings, ICNAAM, 1738, 390014.
39. Guy B, Jackson N., (2015). Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol. 14, 45–54. doi: 10.1038/nrmicro.2015.226639777
40. Robert V., Gibbons et al. (2007). Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequencesAm. J. Trop. Med. Hyg., 77(5), 910–913. 17984352
41. Rocha F., Aguiar M., Souza M., Stollenwerk N.,. (2013). Time-scale separation and center manifold analysis describing vector-borne disease dynamics, Int. J. Comput. Math., 90(10), 2105–2125. doi: 10.1080/00207160.2013.783208
42. Aguiar M., Stollenwerk N., Halstead S.B., (2016). The risks behind Dengvaxia recommendation. The Lancet Infectious Diseases, 16, 882. doi: 10.1016/S1473-3099(16)30168-227477967
43. Bureau of Epidemiology, Ministry of Public Health of Thailand. Weekly epidemiological surveillance report. Retrieved from http://boe-wesr.net/
44. Ruelle David,. (1989). Chaotic evolution and strange attractors. Cambridge University Press. Book http://dx.doi.org/10.1017/CBO9780511608773
45. World Population Prospects: The 2008 Revision Population Database. Retrieved from http://esa.un.org/unpp/index.asp?panel=2
46. World Health Organization. (2015). Dengue and Dengue Hemorrhagic FeverFact sheet 117. Retrieved from http://www.who.int/mediacentre/factsheets/fs117/en/
47. Hadinegoro S.R., Arredondo-García Guy Bo., Bouckenooghe A., Noriega F., Jackson N., (2016). Answer to the review from Halstead and Russell “Protective and immunological behaviour od chimeric yellow fever dengue vaccine”. Vaccine, 34, 4273–4274. doi: 10.1016/j.vaccine.2016.06.01527452651
48. Wilder-Smith A., Vannice K.S., Hambach J., Farrar J., Nolan T., (2016). Populations perspectives and WHO recommendations for CYD-TDV dengue vaccine. J. Infect. Dis., In Press. doi: 10.1093/infdis/jiw34127496977
49. Matheus S., et al. (2005). Discrimination between Primary and Secondary Dengue Virus Infection by an Immunoglobulin G Aviditnoy Test Using a Single Acute-Phase Serum Sample. Journal of Clinical Microbiology, 43, 2793–2797. doi: 10.1128/JCM.43.6.2793-2797.200515956399
50. Halstead S. B., (1994). Antibody-dependent Enhancement of Infection: A Mechanism for Indirect Virus Entry into Cells. Cellular Receptor for Animal Viruses, 28, Chapter 25, 493–516. Cold Spring Harbor Laboratory Press 0-87969-429-7/94.